Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

Stopped Futility for immune responses to the vaccine. Also, a component of study drug was in short supply.

Conditions

• Breast Cancer

Interventions

• BIOLOGICAL: poly-ICLC
• BIOLOGICAL: 9 Peptides from Her-2/neu, CEA, & CTA
• BIOLOGICAL: Peptide-tet

Sponsor

Craig L Slingluff, Jr